Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) — Stella

Home/Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)/

View on ClinicalTrials.gov

Recruiting

Back to Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(2 sites)

China

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong

Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi

Key details

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment target

~10 participants

Started

June 2024

Primary completion

December 2026

Age range

1 Month and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.